Dupont Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Dupont Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,867	Closed	-$292K	–	1253
2019 Q3	$292K	Sell	4,867 -8,610	-64%	-$640K	0.01%	1008
2019 Q2	$1.14M	Buy	13,477 +1,174	+10%	+$106K	0.03%	507
2019 Q1	$1.18M	Hold	12,303	–	–	0.03%	505
2018 Q4	$871K	Hold	12,303	–	–	0.02%	571
2018 Q3	$1.05M	Hold	12,303	–	–	0.02%	554
2018 Q2	$1.43M	Buy	12,303 +5,668	+85%	+$566K	0.03%	458
2018 Q1	$537K	Hold	6,635	–	–	0.01%	662
2017 Q4	$389K	Sell	6,635 -9,598	-59%	-$481K	0.01%	715
2017 Q3	$760K	Hold	16,233	–	–	0.02%	582
2017 Q2	$584K	Sell	16,233 -13,866	-46%	-$443K	0.01%	647
2017 Q1	$927K	Hold	30,099	–	–	0.02%	541
2016 Q4	$1.01M	Hold	30,099	–	–	0.02%	488
2016 Q3	$801K	Buy	+30,099	New	+$699K	0.02%	502
2016 Q2	–	Sell	-13,128	Closed	-$386K	–	678
2016 Q1	$386K	Hold	13,128	–	–	0.01%	573
2015 Q4	$433K	Hold	13,128	–	–	0.01%	580
2015 Q3	$474K	Hold	13,128	–	–	0.01%	542
2015 Q2	$591K	Buy	+13,128	New	+$511K	0.01%	495

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dupont Capital Management's ENTA Position: Q4 2019 in Review

Dupont Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2019, closing a stake of 4,867 shares — an estimated $292K sold.

Dupont Capital Management first reported a position in ENTA in Q2 2015 and held it in 17 quarters. The position peaked at $1.43M in Q2 2018. 171 funds tracked by Wall St. Rank hold ENTA as of Q4 2019.

Dupont Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Dupont Capital Management sold 4,867 Enanta Pharmaceuticals shares in Q4 2019, an estimated $292K.
Dupont Capital Management first reported a position in Enanta Pharmaceuticals in Q2 2015 and held it in 17 quarters.
Dupont Capital Management's Enanta Pharmaceuticals position peaked at $1.43M in Q2 2018.
171 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2019.

Based on Dupont Capital Management's 13F filing for Q4 2019, filed 27 Jan 2020.